Mergers and Acquisitions Managing Director

An M&A Managing Director runs a franchise. The term is deliberate — the clients who call when they're considering a sale, the CEOs who want a second opinion before signing a deal, the corporate development teams who bring their acquisition ideas to you for feedback: those relationships are the product you've spent 12–15 years building, and they're the reason the bank pays you.

The work is almost entirely relationship-based. A senior MD's week involves a board call in the morning, a lunch with a company they've been covering for three years, an internal pitch review in the afternoon, and a flight to meet a client who is six months from a decision they haven't publicly announced yet. The spreadsheet work, the deck construction, the process management — those are the Director's and Associate's job. The MD's job is to be in the room where decisions are made and to give advice that turns out to be right.

That doesn't mean MDs are detached from execution. On a complex transaction — a hostile defense, a distressed sale, a carve-out with complicated accounting — the MD needs to understand the analysis well enough to defend it in front of a skeptical board and a team of opposing advisors. Clients don't pay eight-figure fees for someone who is reading from a deck they didn't build; they pay for someone who has seen 200 transactions and can tell them what this one means.

The organizational responsibilities are real. An MD who doesn't develop junior talent, who hoards client relationships without sharing deal flow with Directors and Associates, or who creates a culture of hours-for-hours'-sake rather than results tends to create groups that lose to competitors on talent retention. The best MDs are explicit about this: building the team is how you build the franchise.

The MD track is not a credentials competition — it's a franchise competition. By the time someone reaches this level, academic qualifications are a distant secondary signal. What matters is deal history, client access, and revenue attribution.

Typical background:

• 12–18 years of M&A investment banking experience
• 3–5 years at Director/VP level with demonstrated origination capacity
• Established network of C-suite and board relationships in a defined sector
• Track record of leading deals with recognized clients and meaningful fee credits

Regulatory requirements:

• FINRA Series 79 (Investment Banking Representative) — required to receive transaction-based compensation
• Series 63 (Uniform Securities Agent State Law Examination) — required in most states
• Ongoing FINRA continuing education requirements

Leadership expectations:

• Building and running a team across multiple deal processes simultaneously
• Managing group P&L including headcount decisions and resource allocation
• Developing Directors who can handle increasing client responsibility

Sector expertise (expected):

• Deep familiarity with 5–10 years of M&A precedents in a defined industry
• Relationships with the leading strategic acquirers, PE sponsors, and management teams in the sector
• Point of view on where value creation opportunities are concentrated and why

Communication at board level:

• Presenting fairly complex valuation and strategic alternatives analyses to directors with no financial background
• Managing dynamics in a boardroom where the CEO and Board may disagree
• Handling press inquiries and public disclosures around transaction announcements

The M&A MD career is not for the majority of people who start in investment banking — but for the minority who reach it, it is one of the most financially rewarding positions in professional services.

Demand for senior M&A advisors is structurally tied to transaction volume and the pace of corporate strategic activity. The 2023 market contraction that followed the 2021–2022 boom resulted in MD-level layoffs at several major platforms — something that had been rare in prior cycles. Banks recalibrated headcount to fee revenue, and MDs without strong origination pipelines were not protected by seniority.

The 2025 recovery has been real, and deal backlogs at several major banks are substantial as companies process strategic decisions deferred during the rate uncertainty of 2023–2024. Sponsor-to-sponsor secondaries, healthcare consolidation, and cross-border technology M&A have all been active. MDs with coverage in these sectors have regained pricing power in the talent market.

The competitive dynamics between bulge-bracket banks and elite boutiques continue to shift. Centerview, Lazard, PJT, and Perella Weinberg have captured disproportionate share on large, complex advisory mandates — partly because independence from underwriting creates better alignment with clients, partly because boutiques offer MDs better economics and more autonomy. The movement of experienced MDs from bulge-bracket platforms to boutiques is an ongoing structural trend, not a cyclical phenomenon.

For someone at MD level or approaching it, the most critical question is: do you have a portable franchise? If your clients follow you, your options are broad — your own boutique, a competing platform, or advisory work under various structures. If your deal flow depends on the bank's brand and distribution, your leverage in the talent market is more constrained.

Dear [Name],

I'm reaching out about the Managing Director opportunity in [Bank/Boutique]'s M&A group. After 14 years in banking — most recently as a Director at [Current Bank] where I've been running execution and building coverage relationships in the [Sector] space — I'm at the point where I want a platform that gives senior bankers more direct origination accountability and a tighter tie between deal contribution and compensation.

Over the past three years, I've developed relationships with the CFO and corporate development teams at 12 companies in [Sector] that are actively evaluating strategic alternatives. Four of those are companies I've worked with on prior mandates; the other eight are coverage relationships I've built through conference work, sector research, and consistent engagement. I've begun bringing mandates to my MD independently, and I'm ready for a platform where that origination is formally credited to my production.

The transactions I've led at the Director level include three sell-side processes above $500M, two buy-side mandates, and a strategic alternatives review that recommended a standalone plan over a sale — advice the board ultimately endorsed and that preserved what turned out to be significant value when industry multiples expanded 18 months later. I know what it means to give advice a client doesn't want to hear, and I know how to maintain the relationship through it.

I'd welcome a conversation about your group's sector priorities and where my coverage relationships might complement what you're building.

[Your Name]